|
HY-13213-50mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-13213-1mL
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-107384A-10mg
|
MedChemexpress LLC
|
Asimadoline (hydrochloride) [CAS 185951-07-9]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-107384A-25mg
|
MedChemexpress LLC
|
Asimadoline (hydrochloride) [CAS 185951-07-9]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-107384A-5mg
|
MedChemexpress LLC
|
Asimadoline (hydrochloride) [CAS 185951-07-9]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-107384A-1mL
|
MedChemexpress LLC
|
Asimadoline (hydrochloride) [CAS 185951-07-9] (10mM in DMSO)
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-107384-10mg
|
MedChemexpress LLC
|
Asimadoline [CAS 153205-46-0]
|
|
COVID-19-immunoregulation
|
|
|
HY-107384-25mg
|
MedChemexpress LLC
|
Asimadoline [CAS 153205-46-0]
|
|
COVID-19-immunoregulation
|
|
|
HY-107384-5mg
|
MedChemexpress LLC
|
Asimadoline [CAS 153205-46-0]
|
|
COVID-19-immunoregulation
|
|
|
HY-107384-1mL
|
MedChemexpress LLC
|
Asimadoline [CAS 153205-46-0] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-17498-1g
|
MedChemexpress LLC
|
Atenolol [CAS 29122-68-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-17498-5g
|
MedChemexpress LLC
|
Atenolol [CAS 29122-68-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-17498-500mg
|
MedChemexpress LLC
|
Atenolol [CAS 29122-68-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-17498-1mL
|
MedChemexpress LLC
|
Atenolol [CAS 29122-68-7] (10mM in DMSO)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-17498S-1mg
|
MedChemexpress LLC
|
Atenolol-d7 [CAS 1202864-50-3]
|
|
|
|
|
HY-17498S-10mg
|
MedChemexpress LLC
|
Atenolol-d7 [CAS 1202864-50-3]
|
|
|
|
|
HY-17498S-5mg
|
MedChemexpress LLC
|
Atenolol-d7 [CAS 1202864-50-3]
|
|
|
|
|
HY-13438-10mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
|
HY-13438-25mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
|
HY-13438-5mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
|
HY-13438-50mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
|
HY-13438-1mL
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-111925-1mg
|
MedChemexpress LLC
|
BI-749327 [CAS 2361241-23-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-111925-10mg
|
MedChemexpress LLC
|
BI-749327 [CAS 2361241-23-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-111925-100mg
|
MedChemexpress LLC
|
BI-749327 [CAS 2361241-23-6]
|
|
COVID-19-immunoregulation
|
|
